CDK
Gli inibitori delle chinasi ciclina-dipendenti (CDK) sono composti che bloccano l'attività delle CDK, un gruppo di chinasi proteiche che regolano il ciclo cellulare, la trascrizione e altri processi cellulari. Le CDK vengono attivate legandosi alle cicline e la loro attività è cruciale per la progressione delle cellule attraverso le diverse fasi del ciclo cellulare. Inibire le CDK può bloccare la divisione cellulare, portando all'arresto del ciclo cellulare e all'apoptosi, in particolare nelle cellule tumorali in cui le CDK sono spesso disregolate. Gli inibitori delle CDK sono ampiamente utilizzati nella ricerca sul cancro e hanno un potenziale terapeutico nel trattamento di vari tipi di cancro. Presso CymitQuimica, offriamo una selezione completa di inibitori delle CDK di alta qualità per supportare la tua ricerca sul controllo del ciclo cellulare, sul cancro e sullo sviluppo terapeutico.
Trovati 578 prodotti per "CDK".
Filtra per
Percentuale di purezza
0
100
|
0
|
50
|
90
|
95
|
100
- Prezzo più basso
- Prezzo più alto
- Purezza più bassa
- Purezza più alta
- Consegna più veloce
JH-XVI-178
CAS:JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.Formula:C22H22ClN7OColore e forma:SolidPeso molecolare:435.909EGFR/CDK2-IN-3
EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.Formula:C30H20N6OSPurezza:98%Colore e forma:SolidPeso molecolare:512.58PROTAC CDK9 degrader-8
PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].Formula:C44H52Cl2N10O7Purezza:98%Colore e forma:SolidPeso molecolare:903.85EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formula:C49H32N12O2S2Purezza:98%Colore e forma:SolidPeso molecolare:884.99SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Formula:C15H14N2OPurezza:99.96%Colore e forma:SolidPeso molecolare:238.2845Multi-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesPurezza:98%Colore e forma:Odour SolidFDA-Approved Kinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Colore e forma:LiquidIV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Formula:C23H32FN5O2SiColore e forma:SolidPeso molecolare:457.6164PROTAC CDK9 degrader 4
CAS:PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.Formula:C43H56N10O5Colore e forma:SolidPeso molecolare:792.97PROTAC CDK2/4 Degrader-1
CAS:PROTACCDK2/4 Degrader-1 (Compound 5) is a potent CDK2/4 PROTAC degrader with a DC50 of ≤ 10 nM for both CDK2 and CDK4. It demonstrates excellent activity in inhibiting cell proliferation in OVCAR3 and T47D cell lines. This compound is applicable for breast cancer and ovarian cancer research.Formula:C31H40F2N8O5SPeso molecolare:674.77PROTAC D16-M1P2
PROTACD16-M1P2 is an orally active PKMYT1 PROTAC degrader with a DC50 of 0.7 nM. It also exhibits inhibitory activity against PKMYT1 with an IC50 of 7.6 nM and inhibits pCDK1 with an IC50 of 9 nM. PROTACD16-M1P2 demonstrates significant antitumor activity in mouse models and is applicable for breast cancer research.DN1679
DN1679 is a potent, selective, and orally active CRBN-dependent dual degrader of CDK12/13 PROTAC. It exhibits DC50 values for CDK12/13 at 8.8/9.8 nM in MDA-MB-231 cells, 5.1/6.4 nM in MDA-MB-157 cells, and 17.2/15.8 nM in MDA-MB-468 cells. DN1679 downregulates mRNA levels of DNA damage response genes such as ATM, ATR, BRCA1, and RAD51. When used in combination with Olaparib, DN1679 shows a significant synergistic anti-tumor effect. It is applicable in research on triple-negative breast cancer.BSJ-03-204
CAS:BSJ-03-204 is a selective Cdk4/6 degrader.Formula:C43H48N10O8Colore e forma:SolidPeso molecolare:832.9CDK9 inhibitor HH1
CAS:CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.Formula:C13H15N3OSPurezza:99.92%Colore e forma:SolidPeso molecolare:261.343CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.Colore e forma:Odour SolidEGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Formula:C24H16N6OS2Purezza:98%Colore e forma:SolidPeso molecolare:468.55CDK4/6-IN-15 hydrochloride
CDK4/6-IN-15 hydrochloride is an orally active selective inhibitor of CDK4/6. It effectively restrains the growth of cancer cells by arresting the cell cycle at the G1 phase. Additionally, CDK4/6-IN-15 hydrochloride inhibits phosphorylation of the retinoblastoma tumor suppressor protein (Rb) at site S780 and suppresses E2 factor (E2F)-regulated gene expression.Formula:C21H28ClFN8SPeso molecolare:478.18302JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formula:C53H69N5O9Purezza:98%Colore e forma:SolidPeso molecolare:920.161LO-3-63
LO-3-63 is a Ribociclib analogue featuring a truncated fumaramide group and acts as a CDK4/6 degrader with PROTAC properties. It degrades CDK4/6 in cells via a CUL4DCAF16-dependent pathway.Colore e forma:Odour SolidCDK5-IN-2
CAS:CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).Formula:C29H28FN5OColore e forma:SolidPeso molecolare:481.56
